LV10201A - Jauni antivielas - superantigena konjugati panemiens to iegusanai panemiens merka sunas lizesanai pielietojums medicina un konjugatu pielietojums arstnieciska sastava iegusanai - Google Patents
Jauni antivielas - superantigena konjugati panemiens to iegusanai panemiens merka sunas lizesanai pielietojums medicina un konjugatu pielietojums arstnieciska sastava iegusanaiInfo
- Publication number
- LV10201A LV10201A LV931362A LV931362A LV10201A LV 10201 A LV10201 A LV 10201A LV 931362 A LV931362 A LV 931362A LV 931362 A LV931362 A LV 931362A LV 10201 A LV10201 A LV 10201A
- Authority
- LV
- Latvia
- Prior art keywords
- applying
- conjugate
- panemans
- dog
- superantigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9002479A SE9002479D0 (sv) | 1990-07-20 | 1990-07-20 | Antibody conjugates |
| SE9002484A SE9002484L (sv) | 1990-07-20 | 1990-07-20 | Nya substituerade polyetrar |
| PCT/SE1991/000496 WO1992001470A1 (en) | 1990-07-20 | 1991-07-16 | Target specific antibody-superantigen conjugates and their preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LV10201A true LV10201A (lv) | 1994-10-20 |
| LV10201B LV10201B (en) | 1995-08-20 |
Family
ID=26660818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-93-1362A LV10201B (en) | 1990-07-20 | 1993-12-22 | Target specific antibody-superantigen conjugates and their preparation |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0610179B1 (lv) |
| JP (1) | JP3334130B2 (lv) |
| KR (1) | KR100189024B1 (lv) |
| AT (1) | ATE144145T1 (lv) |
| AU (1) | AU656906B2 (lv) |
| CA (1) | CA2087164C (lv) |
| DE (1) | DE69122777T2 (lv) |
| DK (1) | DK0610179T3 (lv) |
| ES (1) | ES2094231T3 (lv) |
| GR (1) | GR3022202T3 (lv) |
| HK (1) | HK1007955A1 (lv) |
| HU (1) | HU218603B (lv) |
| LV (1) | LV10201B (lv) |
| NO (1) | NO312816B1 (lv) |
| RU (1) | RU2125889C1 (lv) |
| WO (1) | WO1992001470A1 (lv) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6042837A (en) * | 1989-09-20 | 2000-03-28 | Kalland; Terje | Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC) |
| US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
| US6126945A (en) | 1989-10-03 | 2000-10-03 | Pharmacia Ab | Tumor killing effects of enterotoxins, superantigens, and related compounds |
| US6197299B1 (en) | 1990-07-20 | 2001-03-06 | Pharmacia & Upjohn Ab | Antibody conjugates |
| GB9114399D0 (en) * | 1991-07-03 | 1991-08-21 | Ici Plc | Conjugates |
| SE9102074D0 (sv) * | 1991-07-03 | 1991-07-03 | Kabi Pharmacia Ab | Tomour antigen specific antibody |
| US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
| CA2131528C (en) * | 1992-03-05 | 2004-07-13 | Philip E. Thorpe | Methods and compositions for targeting the vasculature of solid tumors |
| US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| EP0659438A1 (en) * | 1993-12-23 | 1995-06-28 | Boehringer Mannheim Gmbh | Conjugates consisting of peptidic T cell antigens and cell binding groups, and their use for therapy |
| GB9326574D0 (en) * | 1993-12-31 | 1994-03-02 | King S College London | Dry power inhalers |
| SE9402430L (sv) * | 1994-07-11 | 1996-01-12 | Pharmacia Ab | Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten |
| ATE381948T1 (de) * | 1995-05-10 | 2008-01-15 | Kyowa Hakko Kogyo Kk | Cytotoxinkonjugate umfassend dipeptide |
| SE9601245D0 (sv) | 1996-03-29 | 1996-03-29 | Pharmacia Ab | Chimeric superantigens and their use |
| TW517061B (en) | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
| WO2000002587A1 (en) | 1998-07-13 | 2000-01-20 | Board Of Regents, The University Of Texas System | Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
| US6818213B1 (en) | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
| US8025873B2 (en) | 2002-06-20 | 2011-09-27 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
| US8029803B2 (en) | 2002-06-20 | 2011-10-04 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
| US8007805B2 (en) | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4545985A (en) * | 1984-01-26 | 1985-10-08 | The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services | Pseudomonas exotoxin conjugate immunotoxins |
| US4797491A (en) * | 1986-03-17 | 1989-01-10 | Cetus Corporation | Compound 1-(3-(2-pyridyldithio)propionamido)-12-(5-hydrazidoglutaramido)-4,9-dioxadodecane |
| US4806494A (en) * | 1986-07-24 | 1989-02-21 | The United States Of America As Represented By The Department Of Health & Human Services | Monoclonal antibody against ovarian cancer cells (OVB-3) |
| GB8626413D0 (en) * | 1986-11-05 | 1986-12-03 | Gilliland L K | Antibodies |
| US4981979A (en) * | 1987-09-10 | 1991-01-01 | Neorx Corporation | Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity |
| US5004692A (en) * | 1987-12-15 | 1991-04-02 | Protein Design Labs, Inc. | Cloning and expression of phosopholipase C genes |
| IL89504A0 (en) * | 1988-03-08 | 1989-09-10 | Univ Wyoming | Diphtheria toxin derivative,process for the preparation thereof and pharmaceutical composition containing the same |
| EP0334300A1 (en) * | 1988-03-21 | 1989-09-27 | Neorx Corporation | The use of monoclonal antibodies and conjugates thereof as signals to direct sensitized effector cells to tumor sites |
| JPH02196799A (ja) * | 1988-04-08 | 1990-08-03 | Agency Of Ind Science & Technol | 抗ヒト癌蛋白複合体 |
-
1991
- 1991-07-16 JP JP51287191A patent/JP3334130B2/ja not_active Expired - Lifetime
- 1991-07-16 ES ES91914023T patent/ES2094231T3/es not_active Expired - Lifetime
- 1991-07-16 DE DE69122777T patent/DE69122777T2/de not_active Expired - Lifetime
- 1991-07-16 AU AU82941/91A patent/AU656906B2/en not_active Ceased
- 1991-07-16 HU HU9300148A patent/HU218603B/hu not_active IP Right Cessation
- 1991-07-16 CA CA002087164A patent/CA2087164C/en not_active Expired - Lifetime
- 1991-07-16 KR KR1019930700181A patent/KR100189024B1/ko not_active IP Right Cessation
- 1991-07-16 WO PCT/SE1991/000496 patent/WO1992001470A1/en active IP Right Grant
- 1991-07-16 DK DK91914023.6T patent/DK0610179T3/da active
- 1991-07-16 RU RU93004918A patent/RU2125889C1/ru not_active IP Right Cessation
- 1991-07-16 AT AT91914023T patent/ATE144145T1/de not_active IP Right Cessation
- 1991-07-16 EP EP91914023A patent/EP0610179B1/en not_active Expired - Lifetime
-
1993
- 1993-01-19 NO NO19930174A patent/NO312816B1/no unknown
- 1993-12-22 LV LVP-93-1362A patent/LV10201B/en unknown
-
1996
- 1996-12-31 GR GR960403689T patent/GR3022202T3/el unknown
-
1998
- 1998-06-26 HK HK98107094A patent/HK1007955A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP3334130B2 (ja) | 2002-10-15 |
| CA2087164C (en) | 2002-11-26 |
| KR100189024B1 (ko) | 1999-06-01 |
| NO930174L (no) | 1993-01-19 |
| HUT67502A (en) | 1995-04-28 |
| HU9300148D0 (en) | 1993-04-28 |
| CA2087164A1 (en) | 1992-01-21 |
| EP0610179A1 (en) | 1994-08-17 |
| NO312816B1 (no) | 2002-07-08 |
| NO930174D0 (no) | 1993-01-19 |
| ATE144145T1 (de) | 1996-11-15 |
| WO1992001470A1 (en) | 1992-02-06 |
| GR3022202T3 (en) | 1997-03-31 |
| RU2125889C1 (ru) | 1999-02-10 |
| DE69122777D1 (de) | 1996-11-21 |
| HU218603B (hu) | 2000-10-28 |
| AU8294191A (en) | 1992-02-18 |
| LV10201B (en) | 1995-08-20 |
| ES2094231T3 (es) | 1997-01-16 |
| HK1007955A1 (en) | 1999-04-30 |
| AU656906B2 (en) | 1995-02-23 |
| JPH05508856A (ja) | 1993-12-09 |
| DK0610179T3 (da) | 1997-03-24 |
| DE69122777T2 (de) | 1997-04-10 |
| EP0610179B1 (en) | 1996-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LV10201A (lv) | Jauni antivielas - superantigena konjugati panemiens to iegusanai panemiens merka sunas lizesanai pielietojums medicina un konjugatu pielietojums arstnieciska sastava iegusanai | |
| OA07388A (fr) | Nouveaux conjugués associant, par liaison convalente, une enzyme et un anticorps et associations médicamenteuses utilisant lesdits conjugués. | |
| NO924088L (no) | Antistoffer, fremgangsmaate for deres fremstilling og anvendelse dera v | |
| SE8305878L (sv) | Nya azolforeningar | |
| EE04239B1 (et) | Hüdroksüülamiini derivaadid, mis on kasutatavad molekulaarse seostusvalgu moodustumise suurendamiseks, ja nende valmistamine | |
| AR069903A1 (es) | Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer | |
| CA2124218A1 (en) | Cytotoxic drug therapy | |
| SE8605295D0 (sv) | Monoclonal antibodies cross-reactive and crossprotective against p. aeruginosa serotypes | |
| CA2434009A1 (en) | Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy | |
| RU93004918A (ru) | Новые конъюгаты антитело-суперантиген, способ их получения, способ лизирования клетки-мишени, способ лечения и использование конъюгатов для получения фармкомпозиции | |
| SE8700467L (sv) | Monoklonala humanantikroppberedningar som er korsprotektiva | |
| EP0374207B1 (de) | Arzneimittel zur behandlung von krebs, aids und viruserkrankungen | |
| RU95112519A (ru) | (3,4-ди-фторфенокси)метил оксиран и способ его получения | |
| IT7926854A0 (it) | Derivato di creatinolo o-fosfato ad azione terapeutica, procedimento per la sua preparazione e relativ-e composizioni farmaceutiche. | |
| AU539847B2 (en) | 3,4,5-trihydroxypiperidine compounds | |
| DE69724761D1 (de) | Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat | |
| ES508985A0 (es) | Procedimiento microbiologico para la obtencion de un nuevo compuesto antibiotico de la cepa streptomyces. | |
| DK45080A (da) | Fremgangsmaade til fremstilling af anthracyclinglycosider | |
| BR9714945A (pt) | Composição topicamente aplicável para introdução de fármacos peptidaceosos em organismos vivos | |
| MA21989A1 (fr) | Procede de preparation de (pyridyl-3)-2 tetrahydrothiopyrannecarbothioamide -2- oxydes -i- (ir,2r),les (pyridyl-3)-2 tetrahydrothiopyrannecarbothioamide -2- oxydes i (ir,2r) ainsi obtenus et les compositions qui les contiennent . | |
| BR0309786A (pt) | Compostos, seu uso, composição farmacêutica, composição cosmética e uso cosmético de uma composição | |
| EA200300725A1 (ru) | Соединение азола в качестве противогрибковых средств | |
| Joniau et al. | Tumor-specific antibodies in mouse neuroblastoma C 1300 | |
| CA2141025A1 (en) | Anti-mucus glycoprotein monoclonal antibody | |
| WO2023141500A8 (en) | Nanobody-drug adducts and uses thereof |